1.Treatment of infantile subglottic hemangioma with oral propranolol.
Li-xing TANG ; Ya-mei ZHANG ; Gui-xiang WANG
Chinese Journal of Otorhinolaryngology Head and Neck Surgery 2012;47(9):735-738
OBJECTIVETo observe the efficacy of oral Propranolol in the treatment of infantile subglottic hemangioma.
METHODSEleven children (6 females and 5 males) with a median age at onset of treatment being 4 months were included in this study. Propranolol was given after laryngoscopy and a CT scan with contrast of the trachea confirming the presence of a subglottic hemangioma. The starting dose of Propranolol was 0.5 mg/kg per day, given in 2 or 3 divided doses. Heart rate and blood glucose were monitored during the treatment. If no side effects occurred, the dose was increased to 1 mg/kg per day at the third day and to 2 mg/kg per day at the sixth day. Treatment was continued at home after 10 days of inpatient treatment and the children were reevaluated monthly.
RESULTSAfter 24 - 48 hours of treatment, all of the children had improvement in their airway obstruction which was confirmed by fibro-laryngoscopy. The diameter of the subglottic stenosis from the hemangioma decreased from 3.9 - 5.0 mm to 1.5 - 2.0 mm,and the color was also lighter than before. In 3 children with cutaneous hemangioma, there was also significant improvement in the cutaneous lesions after treatment, with the color becoming lighter. There were no significant ECG, blood pressure or blood biochemical changes during the treatment. Two of the children had hypoglycemia at the first dose, but improved after blood transfusion and changing their diet. In five children, the treatment was stopped after 6 to 11 months when the obstructive symptoms improved. None of the children in this group had any evidence of recurrence. In the 5 children who stopped treatment, the obstructing mass in the subglottis was less than 10% of the diameter.
CONCLUSIONOral propranolol is a safe and effective treatment for infantile subglottic hemangioma. It may be used as a first-line therapeutic modality.
Female ; Glottis ; Hemangioma ; drug therapy ; Humans ; Infant ; Laryngeal Neoplasms ; drug therapy ; Male ; Propranolol ; therapeutic use ; Treatment Outcome
2.Construction and identification of recombinant Bb-Eg95 vaccine of Echinococcus granulosus
Bi-ying, ZHOU ; Ya-tang, CHEN ; Wen-gui, LI ; Mei, YANG
Chinese Journal of Endemiology 2009;28(2):218-221
Objective To construct and identify recombinant Bifutobacteria (rBb)-Eg95 vaccine of Echinococcus granulosus (Eg). Methods The total RNA was extracted from hydatid cyst protoscoleces shattered by ultrasound, Eg95 antigen encoding gene was obtained by reverse transcription-polymerase chain reaction(RT-PCR) from the template of total RNA using the primer designed according to the DNA sequence of Eg95, the gene was cloned into Escherichia coli-Bifutobacteria(E.coli-Bb) shuttle plasmid pGEX-1λT and transformed into E.coli BL2 (DE3) competent cell to construct recombinant plasmid pGEX-Eg95 using BamH Ⅰ and EcoR Ⅰ, the recombinant plasmid was identified by restriction endonuclease digestion, then was electroporated into Bb to construct rBb-Eg95 vaccine, the vaccine was identified by PCR. Results Four hundred and seventy-one bp Eg95 gene was amplified by RT-PCR, the products of restriction endonuclease digestion were the same as expected(471 bp Eg95 gene and 4947 bp pGEX-1λT), 471 bp Eg95 gene fragment was amplified by PCR from the template of pGEX-Eg95 extracted from rBb vaccine. Conclusion rBb-Eg95 vaccine of Eg is successfully constructed, which lays the theoretical foundation for exploitation and utilization of this vaccine.
3.Dynamic observation on cytokines of splenocytes in mice immunized with recombinant Bb-Eg95-EgA31 vaccine of Echinococcus granulosus
Bi-ying, ZHOU ; Ya-tang, CHEN ; Wen-gui, LI ; Mei, YANG
Chinese Journal of Endemiology 2010;29(5):508-514
Objective To dynamically observe the changes of cytokines of splenocytes in mice immunized with recombinant bifidobacteria bifidum (Bb)- Eg95-EgA31 vaccine of Echinococcus grauulosus (Eg). Methods Balb/c mice were vaccinated by 5× 108 colony forming unit(CFU) orally and 5 × 105 CFU intranasally, respectively.Mice were killed on week 0,2,4,6,8,10, 12,14,16, 18 and 20 after immunization, respectively, and spleens were separated for cell culture with the stimulation of EgAg, concanavalin A (ConA) or lipopolysaccharide (LPS). The splenocyte supernatants were collected to determine the levels of interferonγ(IFN-γ), interleukin(IL)-12, tumor necrosis factor α(TNF-o) and IL-l0 using enzyme linked immunosorbent assay(ELISA) with MRS as control. Results In the oral immunization group, the levels of IFN-γ, IL-12, TNF-α and IL-10 showed a significant increase from week 2 to week 8, week 2 to week 8, week 4 and week 6 to week 10 after vaccination, respectively, and reached the highest level on week 4, week 2, week 4 and week 6 after vaccination, respectively;in EgAg stimulation group, the levels of IFN-γ, IL-12, TNF-α and IL-10 were (700.0 ± 115.5), (45.0 ± 5.8), (350.0 ± 57.7), (112.5 ± 14.4)ng/L, respectively, compared with week 0[(35.0 ± 5.8), (12.5 ± 2.9), (190.0 ± 11.6), (25.0 ± 5.8)ng/L, P <0.05 or < 0.01] and MRS control group[(37.5 ± 5.0),(13.8 ± 2.5), (195.0 ± 5.8), (27.5 ± 2.9)ng/L, P< 0.05or < 0.01]. In the intranasal immunization group, the levels of IFN-γ, IL-12, TNF-α and IL-10 showed an obvious increase from week 2 to week 8, week 2 to week 8, week 2 to week 6 and week 6 to week 16 after vaccination,respectively, and reached the highest level on week 2, week 2, week 4 and week 8 after vaccination, respectively;in EgAg stimulation group, the levels of IFN-γ, IL-12, TNF-α and IL-10 were (700.0 ± 115.5), (55.0 ± 5.8),(275.0 ± 28.9), (140.0 ± 11.6)ng/L, compared with week 0[(35.0 ± 5.8), (12.5 ± 2.9), (190.0 ± 11.6), (25.0 ±5.8)ng/L, P < 0.05 or < 0.01] and MRS control group[(37.5 ± 5.0), (13.8 ± 2.5), (195.0 ± 5.8), (27.5 ± 2.9)ng/L, P < 0.05 or < 0.01]. The cytokine levels in the groups with EgAg, ConA or LPS stimulus were significantly higher than those in the corresponding splenocytes suspension groups(P < 0.05 or < 0.01) , and the cytokine levels in the groups with ConA or LPS stimulus were obviously higher than those in the corresponding groups with EgAg stimulation(P < 0.05 or < 0.01). Conclusion The mixed Th1 and Th2 type response can be induced in mice immunized with the recombinant Bb-Eg95-EgA31 vaccine of Echinococcus granulosus in the early stage of immunization(2 to 6weeks).
5.Effect of Action Observation Therapy on Upper Limb Function in Children with Spastic Hemiplegic Cerebral Palsy
Ya-Min WEI ; Zhi-Mei JIANG ; Jing-Hua TANG ; Jia-Yin DU ; Xue-Mei LI ; Ya-Nan WANG ; Meng-Qing LI
Chinese Journal of Rehabilitation Theory and Practice 2018;24(4):432-436
Objective To explore the effect of action observation therapy (AOT) on upper limb function in children with spastic hemiplegic cerebral palsy,and the better program. Methods From March to November,2017,45 children with spastic hemiplegic cerebral palsy were randomly assigned to control group and AOT group.The control group was further divided into group A(n=11)and group B(n=11), and received conventional rehabilitation treatment and scenic-observation therapy, 20 minutes every time for group A,and 30 minutes every time for group B.AOT group was further divided into group C(n=10)and group D (n=11), and received AOT in addition, 20 minutes every time for group C, and 30 minutes every time for group D,five times each week for twelve weeks for all the groups.Before treatment,eight and twelve weeks af-ter treatment, they were assessed with hand grip strength, Upper Extremities Functions Test (UEFT), and Wee Functional Independence Measure(WeeFIM). Results After treatment,the hand grip strength and the score of UEFT were better in group D than in groups B and C(P<0.05),and were better at twelve weeks than at eight weeks(P<0.05).No significant difference was found in the score of WeeFIM among groups after treatment(P>0.05). Conclusion AOT could improve upper limp function in children with spastic hemiplegic cerebral palsy,and it's more ef-fective after more training.
7.The comparison of efficacy of different dosage regimen of recombinant human tumor necrosis factor receptor-Fc fusion protein in Chinese ankylosing spondylitis patients
Hui-Qin HAO ; Feng HUANG ; Jie TANG ; Xiao-Hu DENG ; Ya-Mei ZHANG ; Ta-Lin SUO ; Xian-Feng FANG ;
Chinese Journal of Rheumatology 2001;0(04):-
0.05).In addition,in different medication intervals and the same total dosage(200 mg),there was no difference in the number of patients who reached ASAS20,ASAS50 anti BASDAI50 in both groups.The changes of other parameters were not observed.Conclusion Two dosages and different medication interval of rhTNFR-Fc have similiar efficacy onset time and maintenee period.Mean- while,at the same total dosage,there is no signifieant difference in therapeutic effect in the two dosage groups. However,50 mg(1/7 d)regimen has better compliance than 25 mg(1/3 d).
8.The preliminary investigation of tumor necrosis factor-a blocker treatment on CD4~+CD25~+ Treg cells (peripheral blood)in ankylosing spondylitis patients
Hui-Qin HAO ; Feng HUANG ; Xiao-Hu DENG ; Ya-Mei ZHANG ; Jie TANG ; Li-Ping PANG ; Xian-Feng FANG ;
Chinese Journal of Rheumatology 2000;0(06):-
Objective To investigate the role of CD4~+CD25~+ Treg cells on the pathogenesis of ankylos- ing spondylitis(AS), and to study the machanism of tumor necrosis factor(TNF)-?blocker on the treatment of AS by detecting the number of CD4~+D25~+ Treg cells before and after the treatment. Methods The diagno- sis of 10 AS patients was made based on the 1984 modified New York criteria. The patients received subcuta- neou injection of recombinant human tumor necrosis factor receptor-Fc fusion protein(rhTNFR-Fc)(etaner- cept)50 mg weekly for 8 weeks and 10 heathy subjects were enrolled for control. The mononuclear cells were isolated from peripheral blood in beth patients and controls. The number of CD4~+CD25~+ T cells and CD4~+ CD25~(high)T cells and the expression of CTLA-4. were detected by flow cytometry. Results The proportion of CD4~+CD25~+ T cells(24?19)% in total CD4~+ T lymphocytes of peripheral blood and CD4~+CD25~(high)T/CD4~+ T (6?6)% from AS patients before treated with rhTNFR-Fc was higher than that in healthy volunteers and AS patients after treatment(P
9.Relationship between long-tern presence of hypoxic tissue and astrocyte activation after cerebral infarction in rats
Yi-Dong WANG ; Yu QIU ; Jing-Rui PAN ; Mei LI ; Ya-Mei TANG ; Ying PENG
Chinese Journal of Neuromedicine 2009;8(8):781-784
Objective To explore the relationship between the long-term presence of hypoxic tissue and astrocyte activation after cerebral infarction in rats. Methods Middle cerebral artery occlusion was performed in rats to induce permanent brain ischemia (PI group) or transient isehemia for 1.5 h followed by reperfusion (1.5 h IR group). Double immunofluorescence staining with EF5 and gliai fibrillary acidic protein (GFAP) antibodies was used to observe the hypoxic tissue and status of astrocyte activation, respectively. On days 1, 3, 7 and 14 after the operation, GFAP fluorescence intensity and the presence of hypoxic tissue in the ischemic cortex were observed. Results The hypoxic tissues were present from day 3 to day 14 after the operation in 1.5 h IR group, but disappeared after day 3 in PI group. GFAP fluorescence intensity in the hypoxic tissue was significantly higher than that in the surrounding tissues at all the observation time points (P<0.05). GFAP fluorescence intensity increased progressive in both groups with the lapse of time (P<0.05), reaching the peak level on day 7 followed then by gradual declination. On each of the time points for observation, GFAP fluorescence intensity in 1.5 h IR group was significantly higher than that in PI group (P<0.05). Conclusion Astrocyte activation is especially obvious in the hypoxic brain tissues after cerebral infarction, which is closely associated with the long-term existence of hypoxic tissues.
10.Randomized, double-blind, multi-center, positive parallel control clinical trial of compound Wuzhigan capsules on anemopyretic cold.
Xiao-Mei CHEN ; Hui CAO ; Hong SUN ; Jing WEN ; Wen-Hua HUANG ; Ya-Jing HU ; Lin LIN ; Cui-Ying TANG ; Rui XU ; Hai-Tang HU
China Journal of Chinese Materia Medica 2014;39(3):531-535
Compound Wuzhigan capsules is a compound preparation composed of Wuzhigan, Shidagonglao, Gangmei, Shanzhima. A Randomized, double-blind, multi-center, positive parallel control designed to evaluate the clinical efficacy and safety of compound Wuzhigan capsules on anemopyretic cold. One hundred and twenty anemopyretic cold patients were given compound Wuzhigan capsules (test group), 2 capsules one time, three times a day, 119 patients were given compound Wuzhigan tablets (control group) ,4 tablets one time, three times a day; three days of treatment The study showed, the markedly effective rate and total effective rate respectively were 63. 3% and 80% of the test group. For the control group, the markedly effective rate and total effective rate respectively were 72. 5% and 80. 7%. The difference was not statistically significant. Compound Wuzhigan capsules can reduce the dosage, and get better patient compliance.
Adult
;
Capsules
;
Common Cold
;
complications
;
drug therapy
;
Double-Blind Method
;
Drugs, Chinese Herbal
;
adverse effects
;
therapeutic use
;
Female
;
Humans
;
Male
;
Middle Aged
;
Safety
;
Treatment Outcome
;
Young Adult